cyproheptadine has been researched along with Muscle Spasticity in 10 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Muscle Spasticity: A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a free interval) followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this study was to examine how the administration and dosing of the anti-serotonergic medication cyproheptadine hydrochloride (HCl) affects involuntary muscle hypertonicity of the spastic and paretic hands of stroke survivors." | 9.51 | Use of cyproheptadine hydrochloride (HCl) to reduce neuromuscular hypertonicity in stroke survivors: A Randomized Trial: Reducing Hypertonicity in Stroke. ( Bansal, N; Barry, A; Kamper, D; Roth, E; Seo, N; Stoykov, ME; Triandafilou, K; Vidakovic, L, 2022) |
| "The goal of this study was to examine how the administration and dosing of the anti-serotonergic medication cyproheptadine hydrochloride (HCl) affects involuntary muscle hypertonicity of the spastic and paretic hands of stroke survivors." | 5.51 | Use of cyproheptadine hydrochloride (HCl) to reduce neuromuscular hypertonicity in stroke survivors: A Randomized Trial: Reducing Hypertonicity in Stroke. ( Bansal, N; Barry, A; Kamper, D; Roth, E; Seo, N; Stoykov, ME; Triandafilou, K; Vidakovic, L, 2022) |
| "The antiserotonergic agent cyproheptadine was evaluated in six patients as a medication for the management of spasticity due either to spinal cord trauma or to multiple sclerosis." | 5.05 | Action of cyproheptadine in spastic paraparetic patients. ( Barbeau, H; Bédard, PJ; Richards, CL, 1982) |
| "In twenty-five SCI subjects, antispasticity effects of three putative antispasticity agents [clonidine (an alpha-2 noradrenergic agonist), cyproheptadine (a 5-HT2 antagonist) and baclofen (a GABA-B agonist)] were tested in terms of changes in leg tone as graded by the Ashworth scale (AS), in terms of the vibratory inhibition of the H-reflex (VII) and in terms of the ability of the knee to swing passively in the pendulum test as quantified by video motion analysis." | 2.67 | A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. ( Nance, PW, 1994) |
| "Establish the functional impact of the spasticity." | 2.41 | Alpha adrenergic and serotonergic agents in the treatment of spastic hypertonia. ( Nance, PW, 2001) |
| "To evaluate spasticity in a dynamic, voluntary movement such as locomotion, a task-specific approach is essential." | 1.28 | A dynamic EMG profile index to quantify muscular activation disorder in spastic paretic gait. ( Barbeau, H; Fung, J, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamper, D | 1 |
| Barry, A | 1 |
| Bansal, N | 1 |
| Stoykov, ME | 1 |
| Triandafilou, K | 1 |
| Vidakovic, L | 1 |
| Seo, N | 1 |
| Roth, E | 1 |
| Ryu, Y | 1 |
| Ogata, T | 1 |
| Nagao, M | 1 |
| Sawada, Y | 1 |
| Nishimura, R | 1 |
| Fujita, N | 1 |
| Meythaler, JM | 1 |
| Roper, JF | 1 |
| Brunner, RC | 1 |
| Zafonte, R | 1 |
| Lombard, L | 1 |
| Elovic, E | 1 |
| Barbeau, H | 4 |
| Richards, CL | 1 |
| Bédard, PJ | 1 |
| Nance, PW | 2 |
| Fung, J | 2 |
| Stewart, JE | 1 |
| Wainberg, M | 1 |
| Gauthier, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Altering Activation Patterns in the Distal Upper Extremity After Stroke[NCT02418949] | 96 participants (Actual) | Interventional | 2015-11-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Following a maximum voluntary contraction (MVC) -- Time (s) required for muscle electromyographic (EMG) signals to reduce to within 3 SD of pre-MVC EMG activity. (NCT02418949)
Timeframe: baseline and 9 weeks (immediately post intervention)
| Intervention | Seconds (Mean) |
|---|---|
| Cyproheptadine + AMP | -1.66 |
| Placebo for Cyproheptadine + Stretching | -0.96 |
| Cyproheptadine + Stretching | -1.06 |
| Placebo for Cyproheptadine + AMP | -2.65 |
GWMFT is a clinical outcome measure comprised of 15 timed tasks focusing on upper extremity function. Maximum allowable time per task is 120 seconds. (NCT02418949)
Timeframe: baseline and 9 weeks (immediately post intervention)
| Intervention | Seconds (Mean) |
|---|---|
| Cyproheptadine + AMP | -3.66 |
| Placebo for Cyproheptadine + Stretching | -0.51 |
| Cyproheptadine + Stretching | -4.00 |
| Placebo for Cyproheptadine + AMP | -3.89 |
2 reviews available for cyproheptadine and Muscle Spasticity
| Article | Year |
|---|---|
Antispasticity medications: uses and limitations of enteral therapy.
Topics: 4-Aminopyridine; Acetates; Adrenergic alpha-Agonists; Amines; Baclofen; Benzodiazepines; Cyclohexane | 2004 |
Alpha adrenergic and serotonergic agents in the treatment of spastic hypertonia.
Topics: Adrenergic alpha-Agonists; Animals; Anticonvulsants; Clonidine; Cyproheptadine; Humans; Muscle Spast | 2001 |
4 trials available for cyproheptadine and Muscle Spasticity
| Article | Year |
|---|---|
Use of cyproheptadine hydrochloride (HCl) to reduce neuromuscular hypertonicity in stroke survivors: A Randomized Trial: Reducing Hypertonicity in Stroke.
Topics: Cyproheptadine; Humans; Muscle Spasticity; Neuromuscular Agents; Stroke; Stroke Rehabilitation; Surv | 2022 |
Action of cyproheptadine in spastic paraparetic patients.
Topics: Adult; Cyproheptadine; Electromyography; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Musc | 1982 |
A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients.
Topics: Baclofen; Clonidine; Cyproheptadine; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1994 |
The combined effects of clonidine and cyproheptadine with interactive training on the modulation of locomotion in spinal cord injured subjects.
Topics: Adult; Biomechanical Phenomena; Clonidine; Combined Modality Therapy; Cyproheptadine; Double-Blind M | 1990 |
4 other studies available for cyproheptadine and Muscle Spasticity
| Article | Year |
|---|---|
Effects of Treadmill Training Combined with Serotonergic Interventions on Spasticity after Contusive Spinal Cord Injury.
Topics: Animals; Cyproheptadine; Female; Fluoxetine; Muscle Spasticity; Physical Conditioning, Animal; Rats; | 2018 |
Cyproheptadine for intrathecal baclofen withdrawal.
Topics: Acute Disease; Adult; Baclofen; Cerebral Palsy; Cyproheptadine; Diagnosis, Differential; Female; Fev | 2003 |
A dynamic EMG profile index to quantify muscular activation disorder in spastic paretic gait.
Topics: Adult; Cyproheptadine; Electromyography; Humans; Leg; Locomotion; Male; Middle Aged; Muscle Spastici | 1989 |
Quantitative assessment of the effect of cyproheptadine on spastic paretic gait: a preliminary study.
Topics: Adult; Cyproheptadine; Gait; Humans; Male; Middle Aged; Muscle Spasticity; Paralysis | 1986 |